vs
Side-by-side financial comparison of PTC THERAPEUTICS, INC. (PTCT) and ROGERS CORP (ROG). Click either name above to swap in a different company.
ROGERS CORP is the larger business by last-quarter revenue ($200.5M vs $164.7M, roughly 1.2× PTC THERAPEUTICS, INC.). ROGERS CORP runs the higher net margin — 2.2% vs -82.0%, a 84.2% gap on every dollar of revenue. On growth, ROGERS CORP posted the faster year-over-year revenue change (5.2% vs -22.7%). ROGERS CORP produced more free cash flow last quarter ($1.1M vs $-36.6M). Over the past eight quarters, ROGERS CORP's revenue compounded faster (-3.3% CAGR vs -11.5%).
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.
Rogers Corporation is a specialty engineered materials company headquartered in Chandler, Arizona.
PTCT vs ROG — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $164.7M | $200.5M |
| Net Profit | $-135.0M | $4.5M |
| Gross Margin | — | 32.2% |
| Operating Margin | -43.3% | — |
| Net Margin | -82.0% | 2.2% |
| Revenue YoY | -22.7% | 5.2% |
| Net Profit YoY | -104.8% | 421.4% |
| EPS (diluted) | $-1.63 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $200.5M | ||
| Q4 25 | $164.7M | $201.5M | ||
| Q3 25 | $211.0M | $216.0M | ||
| Q2 25 | $178.9M | $202.8M | ||
| Q1 25 | $1.2B | $190.5M | ||
| Q4 24 | $213.2M | $192.2M | ||
| Q3 24 | $196.8M | $210.3M | ||
| Q2 24 | $186.7M | $214.2M |
| Q1 26 | — | $4.5M | ||
| Q4 25 | $-135.0M | $4.6M | ||
| Q3 25 | $15.9M | $8.6M | ||
| Q2 25 | $-64.8M | $-73.6M | ||
| Q1 25 | $866.6M | $-1.4M | ||
| Q4 24 | $-65.9M | $-500.0K | ||
| Q3 24 | $-106.7M | $10.7M | ||
| Q2 24 | $-99.2M | $8.1M |
| Q1 26 | — | 32.2% | ||
| Q4 25 | — | 31.5% | ||
| Q3 25 | — | 33.5% | ||
| Q2 25 | — | 31.6% | ||
| Q1 25 | — | 29.9% | ||
| Q4 24 | — | 32.1% | ||
| Q3 24 | — | 35.2% | ||
| Q2 24 | — | 34.1% |
| Q1 26 | — | — | ||
| Q4 25 | -43.3% | 3.5% | ||
| Q3 25 | 1.4% | 7.3% | ||
| Q2 25 | -19.5% | -33.3% | ||
| Q1 25 | 82.5% | -0.2% | ||
| Q4 24 | -76.2% | -6.6% | ||
| Q3 24 | -27.7% | 6.9% | ||
| Q2 24 | -21.5% | 5.3% |
| Q1 26 | — | 2.2% | ||
| Q4 25 | -82.0% | 2.3% | ||
| Q3 25 | 7.5% | 4.0% | ||
| Q2 25 | -36.3% | -36.3% | ||
| Q1 25 | 73.7% | -0.7% | ||
| Q4 24 | -30.9% | -0.3% | ||
| Q3 24 | -54.2% | 5.1% | ||
| Q2 24 | -53.1% | 3.8% |
| Q1 26 | — | $0.25 | ||
| Q4 25 | $-1.63 | $0.20 | ||
| Q3 25 | $0.20 | $0.48 | ||
| Q2 25 | $-0.83 | $-4.00 | ||
| Q1 25 | $10.04 | $-0.08 | ||
| Q4 24 | $-0.85 | $-0.04 | ||
| Q3 24 | $-1.39 | $0.58 | ||
| Q2 24 | $-1.29 | $0.44 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.9B | $195.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-205.3M | $1.2B |
| Total Assets | $2.9B | $1.4B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $195.8M | ||
| Q4 25 | $1.9B | $197.0M | ||
| Q3 25 | $1.7B | $167.8M | ||
| Q2 25 | $2.0B | $157.2M | ||
| Q1 25 | $2.0B | $175.6M | ||
| Q4 24 | $1.1B | $159.8M | ||
| Q3 24 | $1.0B | $146.4M | ||
| Q2 24 | $1.1B | $119.9M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $-205.3M | $1.2B | ||
| Q3 25 | $-155.8M | $1.2B | ||
| Q2 25 | $-206.5M | $1.2B | ||
| Q1 25 | $-185.8M | $1.3B | ||
| Q4 24 | $-1.1B | $1.3B | ||
| Q3 24 | $-1.1B | $1.3B | ||
| Q2 24 | $-980.2M | $1.3B |
| Q1 26 | — | $1.4B | ||
| Q4 25 | $2.9B | $1.4B | ||
| Q3 25 | $2.6B | $1.4B | ||
| Q2 25 | $2.6B | $1.5B | ||
| Q1 25 | $2.7B | $1.5B | ||
| Q4 24 | $1.7B | $1.5B | ||
| Q3 24 | $1.8B | $1.5B | ||
| Q2 24 | $1.9B | $1.5B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-34.3M | $5.8M |
| Free Cash FlowOCF − Capex | $-36.6M | $1.1M |
| FCF MarginFCF / Revenue | -22.3% | 0.5% |
| Capex IntensityCapex / Revenue | 1.4% | 2.3% |
| Cash ConversionOCF / Net Profit | — | 1.29× |
| TTM Free Cash FlowTrailing 4 quarters | $702.3M | $70.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $5.8M | ||
| Q4 25 | $-34.3M | $46.9M | ||
| Q3 25 | $-66.3M | $28.9M | ||
| Q2 25 | $-58.3M | $13.7M | ||
| Q1 25 | $870.1M | $11.7M | ||
| Q4 24 | $-30.0M | $33.7M | ||
| Q3 24 | $-77.0M | $42.4M | ||
| Q2 24 | $-71.5M | $22.9M |
| Q1 26 | — | $1.1M | ||
| Q4 25 | $-36.6M | $42.2M | ||
| Q3 25 | $-69.7M | $21.2M | ||
| Q2 25 | $-59.6M | $5.6M | ||
| Q1 25 | $868.4M | $2.1M | ||
| Q4 24 | $-33.8M | $18.3M | ||
| Q3 24 | $-77.5M | $25.2M | ||
| Q2 24 | $-78.8M | $8.8M |
| Q1 26 | — | 0.5% | ||
| Q4 25 | -22.3% | 20.9% | ||
| Q3 25 | -33.1% | 9.8% | ||
| Q2 25 | -33.3% | 2.8% | ||
| Q1 25 | 73.8% | 1.1% | ||
| Q4 24 | -15.8% | 9.5% | ||
| Q3 24 | -39.4% | 12.0% | ||
| Q2 24 | -42.2% | 4.1% |
| Q1 26 | — | 2.3% | ||
| Q4 25 | 1.4% | 2.3% | ||
| Q3 25 | 1.6% | 3.6% | ||
| Q2 25 | 0.7% | 4.0% | ||
| Q1 25 | 0.1% | 5.0% | ||
| Q4 24 | 1.8% | 8.0% | ||
| Q3 24 | 0.3% | 8.2% | ||
| Q2 24 | 4.0% | 6.6% |
| Q1 26 | — | 1.29× | ||
| Q4 25 | — | 10.20× | ||
| Q3 25 | -4.17× | 3.36× | ||
| Q2 25 | — | — | ||
| Q1 25 | 1.00× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 3.96× | ||
| Q2 24 | — | 2.83× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
